BioMedNewsBreaks

FridayJul 11, 2025 2:44 pm

BioMedNewsBreaks — Rare Biotech Story: Nutriband Inc. (NASDAQ: NTRB) Featured on Smart Money Podcast

Nutriband (NASDAQ: NTRB) was recently featured on the Smart Money Circle Show, where Serguei Melnik, NTRB’s founder and president, unveiled his no-nonsense approach to biotech entrepreneurship. Standing in stark contrast to the conventional playbook are his grounded tone and unwavering focus on long-term value. An article discussing this reads, “Unlike most early-stage biotech companies, Nutriband generates revenue today. The company operates a manufacturing facility in North Carolina that produces the Active Intelligence tape used by Reebok, among others. The company also recently launched a mosquito-repelling patch, now approved for sale in Costa Rica. Melnik and his team personally tested the product by…

Continue Reading

FridayJul 11, 2025 9:00 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines 

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.” The article highlights Calidi’s next-generation platform, which uses engineered viruses to deliver genetic therapies directly to primary and metastatic tumors. While oncology is the company's initial focus, it is also evaluating applications in autoimmune disorders, underscoring its broader therapeutic potential. The editorial emphasizes Calidi’s role in addressing the rising global cancer burden and advancing transformative treatment options.  To view the full press release, visit: https://ibn.fm/tRB9D About Calidi Biotherapeutics  Calidi Biotherapeutics is a clinical-stage immuno-oncology…

Continue Reading

ThursdayJul 10, 2025 11:37 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $4.6 Million Through Warrant Exercise Agreement

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a definitive agreement for the immediate cash exercise of outstanding warrants totaling 6,595,000 shares of common stock at a reduced price of $0.70 per share. The transaction is expected to generate approximately $4.6 million in gross proceeds. In exchange, the company will issue new unregistered warrants with the same share count, exercisable in six months at $0.70 and valid for five and a half years. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. Calidi plans to use the net proceeds…

Continue Reading

WednesdayJul 09, 2025 1:56 pm

BioMedNewsBreaks — Adageis’ Platform Tackles Healthcare Complexities with AI

Adageis was featured in a recent article that discussed its powerful and patented AI-centric software solution. “Healthcare is a complicated place, and navigating the system is extremely difficult for patients,” Adageis’ CEO Shane Speirs was quoted as saying. “What Adageis does is provide a simple solution to healthcare organizations, ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with.” To view the full article, visit https://ibn.fm/i5Oo0 About Adageis Adageis is a healthcare technology innovator focused…

Continue Reading

WednesdayJul 09, 2025 11:31 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment 

  CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on treating primary and metastatic cancers in the brain and central nervous system, announced CEO John Climaco’s participation in a Virtual Investor CEO Connect segment. Climaco provided an overview of the Company’s lead candidate, TPI 287, and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, Massachusetts. To view the full press release, visit https://ibn.fm/9Trwm About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.…

Continue Reading

WednesdayJul 09, 2025 9:00 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet’s Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities…

Continue Reading

TuesdayJul 08, 2025 3:04 pm

BioMedNewsBreaks — Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. “HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection, but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking,” reads a recent article. “As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus…

Continue Reading

TuesdayJul 08, 2025 12:18 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform 

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer. To view the full press release, visit: https://ibn.fm/nMiOZ About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed…

Continue Reading

WednesdayJul 02, 2025 11:40 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Declares 25% Preferred Stock Dividend Linked to AVERSA Fentanyl Approval 

Nutriband (NASDAQ: NTRB) announced that its Board of Directors has approved a 25% preferred stock dividend, granting one preferred share for every four common shares held as of July 25, 2025, with distribution set for August 5. Each preferred share will convert to one common share upon FDA approval of the Company’s AVERSA Fentanyl product. If not converted, preferred shares will be eligible for annual cash dividends from company profits at the Board’s discretion. CEO Gareth Sheridan said the move reflects the Company’s commitment to shareholder value as it advances toward AVERSA commercialization. To view the full report, visit https://nnw.fm/NdG7s…

Continue Reading

TuesdayJul 01, 2025 9:40 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Added to Four Russell Indexes in 2025 Reconstitution

Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. sales between $80 million and $200 million. Russell indexes, maintained by FTSE Russell, benchmark approximately $10.6 trillion in assets and are widely used by investment managers and institutions. To view the full report, visit https://ibn.fm/wa35e About Nutriband Inc. Nutriband is primarily engaged in the development…

Continue Reading